Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20495355 | 0.77 | LMNA (0.39) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL31145674 | 0.75 | OR51E2 (0.42) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL27530727 | 0.71 | GPR84 (0.48) | LMNACA12CA1CA9 | |
| SCHEMBL18783157 | 0.71 | SMN1; SMN2 (0.36) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL9689376 | 0.71 | LMNA (0.42) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL3056305 | 0.70 | GABRR1 (0.37) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL3056302 | 0.70 | DPP4 (0.34) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL1615608 | 0.69 | LMNA (0.40) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL1964784 | 0.69 | LMNA (0.40) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL17652005 | 0.69 | LMNA (0.40) | LMNACA12CA1CA9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129014-B1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | TETRAHEDRON (FR) | 2021-05-12 | — | — | EP | claimed |
| US-10308602-B2 | Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents | TETRAHEDRON (FR) | 2019-06-04 | — | — | US | claimed |
| US-20170114011-A1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS ANTITUMOR AGENTS | TETRAHEDRON (FR) | 2017-04-27 | — | — | US | claimed |
| EP-3129014-A2 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | Tetrahedron (FR) | 2017-02-15 | — | — | EP | claimed |
| EP-3129014-B1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | TETRAHEDRON (FR) | 2021-05-12 | — | — | EP | disclosed |
| US-10308602-B2 | Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents | TETRAHEDRON (FR) | 2019-06-04 | — | — | US | disclosed |
| US-20170114011-A1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS ANTITUMOR AGENTS | TETRAHEDRON (FR) | 2017-04-27 | — | — | US | disclosed |
| EP-3129014-A2 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | Tetrahedron (FR) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114011-A1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS ANTITUMOR AGENTS | SCLY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC7A5 | LMNA 4576/4885CA12 1965/4885CA1 1060/4885 |
| US-10308602-B2 | Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents | SCLY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT5 | LMNA 4592/4885CA12 2003/4885CA1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.